Tuberculosis
The Latest
Joint Action and Service Integration Needed to Tackle HIV and TB During COVID-19 Pandemic, Experts Agree
Global health leaders warn that the pandemic may impact health systems and worsen the world's pre-existing epidemics.
The Opioid Epidemic Is Fueling HIV Cluster Outbreaks -- Here's How the CDC is Responding
Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.
TB Causes 1 in 3 HIV Deaths
In 2017, 300,000 of the total 940,000 global HIV deaths occurred among people infected by both HIV and tuberculosis (TB), according to the WHO "Global TB report 2018" launched last week.
Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment
New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.
Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.
Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin
A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.
Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine
Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.
Twice-Daily Tenofovir Alafenamide Dose Might Overcome Interaction With Rifampicin
Twice-daily tenofovir alafenamide plus rifampicin provided similar exposures to once-daily TAF in a pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.
Dolutegravir-Based ART in Combination With Rifampicin-Based TB Treatment Is Safe in a Small Cohort of Co-Infected Patients
Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016.
Why Taking Vitamin D Pills Could Help the Fight Against TB and HIV
In countries such as South Africa with a high burden of TB and HIV, vitamin D could be an extremely effective and cheap weapon to include in the arsenal against the diseases.